Retatrutide (laboratory code LY3437943) is one of the most closely watched compounds in metabolic peptide research. Developed by Eli Lilly, it is designed to activate three separate hormone receptors in a single molecule: GIP, GLP-1, and glucagon. This “triple agonist” design places it a step beyond dual-agonist tirzepatide and single-agonist semaglutide, and early trial data have made it a frequent reference point in obesity and metabolic research literature. This guide summarizes what retatrutide is, how its proposed mechanism works, and the key research considerations for anyone studying this compound, strictly for laboratory and educational purposes.
What is Retatrutide?
Retatrutide is a synthetic peptide engineered as a triple hormone-receptor agonist, meaning it is designed to bind and activate three separate G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. It is administered once weekly in the study protocols where it has been evaluated, a pharmacokinetic profile achieved through a fatty-acid side chain that extends circulating half-life, similar in concept to other long-acting incretin peptides.
Retatrutide is not an approved medicine. As of mid-2026 it remains an investigational compound in Eli Lilly’s clinical development program, having progressed from early-phase studies into a Phase 3 program known as TRIUMPH. Reference material used in laboratory research is available at the 5mg and 10mg concentrations, intended strictly for non-clinical, research-only use.
Mechanism of Action
Retatrutide’s defining feature is that it engages three metabolically relevant pathways with a single molecule, rather than one or two.
GLP-1 Receptor Activation
- Slows gastric emptying, which is associated with prolonged satiety
- Signals appetite-related centers in the hypothalamus
- Enhances glucose-dependent insulin secretion
- Suppresses glucagon release in the postprandial state
GIP Receptor Activation
- Contributes additional insulinotropic signaling
- Is studied for effects on adipose tissue handling and insulin sensitivity
- May act synergistically with GLP-1 signaling on appetite and energy balance
Glucagon Receptor Activation
This is the pathway that distinguishes retatrutide from dual agonists such as tirzepatide. Native glucagon is typically associated with raising blood glucose, but in the context of this multi-receptor design, glucagon receptor agonism is studied for a different set of effects:
- Increased energy expenditure
- Enhanced hepatic fat oxidation
- Potential contributions to lipid metabolism beyond what GLP-1 and GIP activation alone appear to produce
Because glucagon signaling can independently raise glucose, the balance struck between all three receptors in retatrutide’s design is central to the hypothesis that it can improve body-weight and metabolic endpoints without net adverse glycemic effects. This three-way balance is an active area of ongoing pharmacological research rather than a settled mechanism.
Retatrutide vs Tirzepatide vs Semaglutide
The distinction between these three widely studied incretin-pathway compounds comes down to receptor count and, correspondingly, the breadth of downstream signaling studied:
| Compound | Receptors Targeted | Generation |
|---|---|---|
| Semaglutide | GLP-1 (single agonist) | 1st |
| Tirzepatide | GIP + GLP-1 (dual agonist) | 2nd |
| Retatrutide | GIP + GLP-1 + Glucagon (triple agonist) | 3rd |
Semaglutide established that single-pathway GLP-1 agonism could produce clinically meaningful weight-related outcomes. Tirzepatide’s dual-agonist design was associated with larger average effects in head-to-head research settings. Retatrutide extends this hypothesis one step further by adding glucagon receptor engagement, which researchers propose may contribute an energy-expenditure component that GLP-1 and GIP agonism alone do not appear to replicate. A detailed side-by-side breakdown of dosing history, trial design, and reported outcomes for all three compounds is available in the semaglutide, tirzepatide, and retatrutide comparison, and retatrutide is also discussed alongside other emerging candidates in the next-generation weight-loss peptides overview.
Highest-dose figures from separate trials; cross-trial comparisons are illustrative only, since populations and durations differ.
Research Background and Key Findings
The Phase 2 Trial (Jastreboff et al., 2023)
The foundational clinical dataset for retatrutide is the Phase 2 trial published in the New England Journal of Medicine by Jastreboff and colleagues in 2023, “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” This randomized, double-blind, placebo-controlled study enrolled adults with obesity or overweight (without type 2 diabetes) and evaluated multiple retatrutide dose levels over 48 weeks. The trial reported mean body-weight reductions reaching approximately 24% at the highest studied dose by week 48, among the largest reductions reported in a controlled trial of a pharmacological agent for obesity at that time. The accompanying NEJM editorial characterized the class of triple hormone-receptor agonists as a notable step forward in obesity pharmacotherapy research.
Extension Studies and Additional Endpoints
Since the original Phase 2 publication, retatrutide has also been studied in a Phase 2a trial for metabolic dysfunction-associated steatotic liver disease (MASLD), examining whether the compound’s proposed hepatic and lipid-oxidation effects extend to liver fat outcomes. Longer follow-up data from Phase 2 cohorts have also been reported, describing further weight reduction at extended time points beyond 48 weeks.
Phase 3 Program (TRIUMPH)
Retatrutide has since advanced into a Phase 3 program named TRIUMPH. Eli Lilly has reported topline results from multiple TRIUMPH trials, including data on body-weight endpoints and, in at least one trial, joint-pain outcomes in participants with knee osteoarthritis. These Phase 3 readouts are recent, are being reported progressively through 2026, and should be treated as emerging, company-reported data pending full peer-reviewed publication. Researchers should consult the primary trial publications and regulatory filings directly rather than relying on secondary summaries for any quantitative claim.
- 1
Phase 2 (2023)
NEJM obesity trial (Jastreboff et al.), ~24% weight reduction over 48 weeks.
- 2
Phase 2a MASLD
Studied for liver-fat and lipid-oxidation outcomes.
- 3
Extended follow-up
Further weight reduction reported beyond 48 weeks.
- 4
Phase 3 TRIUMPH
Company-reported topline body-weight and knee-osteoarthritis readouts through 2026.
Important caveat: No dose, schedule, or outcome described above is a treatment recommendation. All figures originate from controlled clinical trial reporting and are presented here for research-literacy purposes only.
Forms, Reconstitution and Handling
Research-grade retatrutide is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution with an appropriate diluent, such as bacteriostatic water, before it can be used in a laboratory setting. Because the resulting concentration depends entirely on the diluent volume added, careful calculation and documentation are essential for reproducible research. A general walkthrough of diluent selection, draw-volume calculation, and concentration recordkeeping is provided in the peptide reconstitution guide. Concentration-specific reference data corresponding to common research vial sizes can be found on the retatrutide 5mg and retatrutide 10mg pages.
Research Considerations
Several general considerations recur in the literature and in laboratory practice when this compound is studied:
- Multi-receptor pharmacology adds complexity. Because retatrutide engages three distinct receptor systems, isolating the contribution of any single pathway in an experimental design requires careful controls.
- Gastrointestinal tolerability signals (nausea, vomiting, diarrhea) have been reported across the incretin-agonist class, consistent with GLP-1 pathway engagement, and dose-escalation designs in clinical trials have been used to manage this.
- Comparative study design matters. Cross-trial comparisons between retatrutide, tirzepatide, and semaglutide should be interpreted cautiously, since trial populations, durations, and endpoints differ.
- Investigational status. As a compound still in Phase 3 development, retatrutide’s full safety and efficacy profile is not yet established in the way that an approved medicine’s would be.
None of the above constitutes a recommendation for use; it summarizes general themes discussed in the published research record.
Storage and Stability
General handling principles that apply broadly to lyophilized incretin-pathway peptides include:
- Unreconstituted (lyophilized) powder: store refrigerated; many research protocols specify freezer storage for extended-duration retention.
- After reconstitution: keep refrigerated (commonly cited as roughly 2-8 degrees C) and protect from light.
- Avoid repeated freeze-thaw cycling, vigorous agitation, and prolonged exposure to room temperature, all of which are associated with peptide degradation.
- Label every vial with reconstitution date, diluent volume, and calculated concentration to preserve traceability across an experiment or study.
These are general laboratory-handling principles rather than a validated stability protocol specific to retatrutide, whose formal stability data have not been broadly published in the peer-reviewed literature at the time of writing.
Safety, Legality and Research Disclaimers
Retatrutide sold or described as a research chemical is not an approved pharmaceutical product and is not equivalent to any medicine cleared by a regulatory authority. It is intended exclusively for laboratory and educational research, not for human or veterinary use.
- Reported adverse events in the clinical trial literature are predominantly gastrointestinal, consistent with the broader incretin-agonist class.
- Regulatory and legal status varies by jurisdiction and continues to evolve as the compound advances through Phase 3 development; researchers are responsible for verifying and complying with local laws, import regulations, and institutional biosafety or ethics requirements.
- Any research use should follow the governing policies of the relevant institution or laboratory.
This article is educational in nature and does not constitute medical advice, and nothing in it should be interpreted as a recommendation to obtain, administer, or use retatrutide outside of an authorized research setting.
Related reading
- Retatrutide phase 3 results: TRIUMPH-1
- Retatrutide dysesthesia: the tingling, explained
- GLP-1 and knee osteoarthritis
Frequently Asked Questions
What does “triple agonist” mean?
It means the molecule is designed to bind and activate three distinct receptors, GIP, GLP-1, and glucagon, rather than one (as with semaglutide) or two (as with tirzepatide). Each pathway is studied for a distinct contribution to metabolic outcomes.
Is retatrutide approved for use?
No. As of mid-2026, retatrutide remains investigational and is progressing through Eli Lilly’s Phase 3 TRIUMPH clinical trial program. It has not received regulatory approval.
How does retatrutide differ from tirzepatide?
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds a third target, the glucagon receptor, which is studied for a possible additional effect on energy expenditure and hepatic fat oxidation.
What was the key finding of the Jastreboff et al. 2023 trial?
The Phase 2 trial, published in the New England Journal of Medicine, reported mean body-weight reductions of roughly 24% at the highest dose studied over 48 weeks in adults with obesity or overweight without type 2 diabetes.
How should reconstituted retatrutide be stored in a lab setting?
General practice calls for refrigeration (commonly cited around 2-8 degrees C), protection from light, and avoidance of repeated freeze-thaw cycles, with every vial labeled by date and concentration.
Can I purchase retatrutide for personal use?
This article does not endorse or facilitate acquisition for personal or clinical use. Retatrutide is discussed here strictly as a research compound; any acquisition or handling must comply with local law and be limited to authorized research contexts.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 2023.
- Rosenstock J, et al. “Triple G Agonists — A Home Run for Obesity?” (Editorial). New England Journal of Medicine, 2023.
- “Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial.” Nature Medicine / PMC, 2024.
- Eli Lilly and Company. “Lilly’s Triple Agonist, Retatrutide, Delivered Weight Loss… in First Successful Phase 3 Trial” (TRIUMPH program topline results). Investor news release, 2025.
- “Retatrutide — A Game Changer in Obesity Pharmacotherapy” (Review). Biomolecules / PMC, 2025.
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption.